Keratoacanthoma - Keratoakantom
☆ V rezultatih raziskave Stiftung Warentest iz Nemčije leta 2022 je bilo zadovoljstvo potrošnikov z ModelDermom le nekoliko nižje kot s plačanimi telemedicinskimi svetovanji.
Običajno Keratoakantom (Keratoacanthoma)
References
Keratoacanthoma (KA) je pogost kožni tumor, znan po hitri rasti in možnosti, da sam od sebe nazaduje. Običajno se pojavi pri starejših, svetlopoltih moških z anamnezo poškodb zaradi sonca. Čeprav je običajno zdravljenje kirurška odstranitev z ekscizijo ali Mohsovo mikrografsko operacijo, so na voljo različne druge možnosti zdravljenja.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) je tumor nizke stopnje, ki se začne v določenih žlezah v koži in je pod mikroskopom podoben squamous cell carcinoma (SCC) . V teku je razprava o tem, ali bi bilo treba KA opredeliti kot obliko invazivnega SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) je druga najpogostejša vrsta raka pri ljudeh, zlasti pri starejših. Kirurgija se običajno uporablja za zdravljenje cSCC, toda pri nekaterih bolnikih, ki ne morejo opraviti operacije ali se zanjo ne odločijo, je mogoče razmisliti o drugih možnostih, kot je zdravljenje z intralezijo. Uporabljena so bila tradicionalna intralezijska zdravljenja (methotrexate or 5-fluorouracil) , vendar potekajo raziskave novih pristopov, kot sta intralezijska imunoterapija in onkolitična viroterapija. Tu si bomo ogledali različna intralezijska zdravljenja cSCC, od klasičnih metod do najsodobnejših strategij.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pod mikroskopom je keratoakantom (keratoacanthoma) zelo podoben ploščatoceličnemu karcinomu. Medtem ko nekateri patologi klasificirajo keratoakantom (keratoacanthoma) kot ločeno entiteto in ne kot maligno bolezen, približno 6 % kliničnih in histoloških keratoakantom (keratoacanthoma) napreduje v invazivne in agresivne ploščatocelične rake.
○ Diagnoza in zdravljenje
#Dermoscopy
#Skin biopsy